S
Segmed
High-quality, anonymous medical AI data that can empower the business, and change lives
About Segmed
Segmed.ai is a technology startup that operates in the healthcare sector, specifically in the field of medical data acquisition and management. The company provides a platform that allows access to millions of de-identified, standardized medical images and records for research and development (R&D) purposes. This service is particularly beneficial for artificial intelligence (AI) teams working on healthcare projects that require large volumes of diverse medical data.
Read full description
The company's primary clients are clinical operations executives, AI teams, and healthcare organizations. Segmed.ai's business model revolves around providing these clients with the necessary data for their R&D needs, thus accelerating their project timelines. The company ensures that the data is machine-readable and can be delivered within days, which is a significant advantage in the fast-paced medical R&D field.
In addition to providing data, Segmed.ai also offers a service to healthcare organizations to establish a passive revenue stream from their untapped medical data assets. This means that healthcare organizations can monetize their patient data by making it available for medical research, while also ensuring that their patient population's data is included in the latest research.
Segmed.ai generates revenue by charging clients for access to their vast database of medical images and records. The company also earns income from the passive revenue streams it helps establish for healthcare organizations.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Palo Alto, United States
- Employees
- 48
- Open positions
- 1
- Dealroom signal
- 79.2/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Tech for Hospitals and Clinics, Tech for Medical Professionals, Biotech and Pharma, AI for medical imaging, Physician Support Tools, Techbio
- Technology
- Artificial Intelligence
- Business model
- SaaS
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Segmed.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Sep 2024 | $10M | $42M | Blumberg Capital · Fox Chase Cancer Center · Engine Health Capital · Y Combinator | ↗ |
| SEEDOther financing | Nov 2022 | $5.2M | $21M | M3 · Alchemist Accelerator · IGan Partners · Expeditions Fund | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Segmed is 4.6K monthly website visits, down 19.3% over the last three months. Segmed's team grew 6.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 Keen EyeAnalyzes and reviews slide images |
Paris, France | Closed | 7 | $8.3M | $26M |
 UltromicsAI-powered echocardiogram analysis for heart failure detection. |
Oxford, United Kingdom | Operational | |||
 OptellumDeveloping an artificial intelligence software platform to support clinicians in lung cancer nodule management |
Oxford, United Kingdom | Operational | |||
 Aiforia TechnologiesAI-powered pathology image analysis software for researchers |
Helsinki, Finland | Operational | |||
 SaventicAI-powered platform supporting rare disease diagnosis |
Toruń, Poland | Operational | |||
 NotableAI platform automating healthcare administrative workflows |
San Mateo, United States | Operational | |||
 AlgoDxDeveloping a new category of diagnostics in the form SaMD |
Stockholms kommun, Sweden | Operational | |||
 ArtiQHas developed AI-based software to help doctors save time and improve interpretation of lung function tests and diagnosis of lung diseases |
Leuven, Belgium | Acquired |
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed8 investors entered at this stage
Y Combinator
Blumberg Capital
Nina Capital
Mighty Capital
M3
Alchemist Accelerator
IGan Partners
Expeditions Fund
Series A6 investors entered at this stage
Advocate Health
Fox Chase Cancer Center- ECEngine Health Capital
- CGCastellan Group
Nova Capital
Bold Brain Ventures
Other known investors4 additional known investors
1P1Y
Donatella Callegaris
Julian Wichmann
StartX
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Segmed on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Segmed’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.